Jennifer has over 20 years of experience as an oncologist specializing in early drug development in academia and industry - as an Associate Professor at MD Anderson Cancer Center, a Clinical Program Leader at The Novartis Institutes for BioMedical Research (NIBR) and a Chief Medical Officer in small biotech. At MD Anderson she was the Principal Investigator on over 30 Phase 1/2 trials and co-author of 145 peer-reviewed publications. In industry, Jennifer has built and led teams to early milestones including anti-PD-L1 antibody FAZ053, the first Novartis immunotherapy compound to achieve clinical proof-of-concept in dose escalation, HER2-TLR7/8 immune stimulatory antibody conjugate NJH395 (Novartis), and bifunctional EGFR/TGFb Trap fusion protein BCA101 (Bicara Therapeutics).
Jennifer completed a breast medical oncology fellowship at Memorial Sloan Kettering, a medical oncology fellowship at Yale Cancer Center and an internal medicine residency at Columbia University / NewYork-Presbyterian Hospital. She earned an M.D. from Cornell Medical College and an A.B. in Art History from Princeton University.
She is the Founder of Collage, a nonprofit that provides personalized art programs for patients living with cancer.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.